MDC-Verte Fund Welcomes Three Innovative Companies to Its Portfolio

The MDC-Verte Fund, a joint venture between MDC-Studio and the Verte Opportunity Zone Fund, has announced the addition of three groundbreaking medical technology companies to its portfolio. These strategic investments align with the Fund’s mission to drive innovation in health and medicine, particularly within Opportunity Zones across the United States.

This joint venture brings together MDC-Studio and the Verte Opportunity Zone Fund. MDC-Studio is an innovation-focused venture studio based in Baltimore dedicated to supporting early-stage companies in the healthcare and life sciences sectors. The studio provides hands-on operational support, strategic guidance, and access to critical funding, accelerating healthcare solutions from concept to commercialization. The Verte Opportunity Zone Fund is a specialized investment fund committed to fostering economic growth in underserved communities through strategic investments in high-potential businesses. 

Fueling Early-Stage Medical Innovation

The MDC-Verte Fund was established to provide critical early-stage capital to emerging medtech companies, bridging the gap between ideation and later-stage investment. By combining venture investment with non-dilutive funding from federal and state agencies, the Fund offers startups an alternative to traditional funding sources, such as personal networks or angel investors.

New Portfolio Additions

Surgical Vision Systems

Surgical Vision Systems is revolutionizing surgical safety and efficiency with its SVS Instrument Sterilization and Delivery System. This cutting-edge robotic system tackles a major challenge in healthcare by reducing the cost and complexity of cleaning and sterilizing surgical instruments. Additionally, its advanced staining and image processing technology enhances infection prevention, improving patient safety while reducing healthcare costs.

Connected Care Systems

Connected Care Systems is transforming dementia care with its ARGON Wearable System, designed to support individuals with dementia and their caregivers. Utilizing low-cost, ultra-wideband wearable tags and wall-mounted transceivers, the system tracks daily activities and caregiver interactions. This innovative approach promotes engagement, enhances caregiving efficiency, and ultimately improves the quality of life for individuals with dementia.

IMERSE Surgical Robotics

IMERSE Surgical Robotics is pioneering advancements in vascular microsurgery with its semi-autonomous robotic suturing system. By integrating advanced imaging and machine learning, this technology enables surgeons to suture tiny blood vessels with unprecedented precision, reducing complications and improving patient recovery times.

Expanding a High-Impact Portfolio

With the addition of these three companies, the MDC-Verte Fund now supports a total of five innovative medtech startups. The Fund’s commitment to fostering high-growth companies in Opportunity Zones addresses a critical funding gap. While Opportunity Zone investments are traditionally focused on real estate, fewer than 4% support businesses, and an even smaller fraction target startups. The MDC-Verte Fund seeks to change this dynamic by directing capital toward promising medical technology companies, fostering both innovation and job creation in economically distressed communities.

By supporting transformative healthcare solutions, the MDC-Verte Fund continues to drive meaningful impact in the medtech space, ensuring that groundbreaking innovations reach the market and improve patient outcomes nationwide.